The growing popularity of GLP-1 drugs opens up massive opportunities for biopharma companies, life sciences firms and ...

A new poll found that one in eight American adults had used a GLP-1 drug, with half of those people still taking the ...

Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim ...

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of ...

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results ...

RBC Capital Markets initiates Corbus Pharmaceuticals at outperform, highlighting the potential of an antibody-drug conjugate ...

A poll from the health policy nonprofit KFF found that 1 in 8 adults say they’ve taken a GLP-1 agonist, the obesity and ...

Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24Top-line ...

The EMERGENT-3 trial, published in the Journal of the American Medical Association Psychiatry,  represents a significant ...

Fintel reports that on May 13, 2024, RBC Capital initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a ...

The Boston Globe: First Recipient Of Genetically Engineered Pig Kidney Has Died Rick Slayman, the first man to receive ...

Q1 2024 Earnings Call Transcript May 11, 2024 Trevi Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge ...